Condition
Oligodendrogliomas
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
Termination Rate
33.3%
2 terminated out of 6 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed4
Terminated2
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03027388Phase 2Completed
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
NCT02388659Completed
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
NCT02023905Phase 2Terminated
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
NCT02731521Completed
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
NCT00897377Phase 3Terminated
Treatment Strategy for Low-grade Gliomas
NCT00213876CompletedPrimary
Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours
Showing all 6 trials